Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101
May 15, 2017 08:15 ET
|
Minerva Neurosciences, Inc.
Advancing a new potential therapeutic paradigm for the treatment of negative symptoms, a key unmet need in schizophrenia and other brain diseasesCompany to host conference call on May 16, 2017 at...